Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Revealed: It costs £42,000 to support a child through 3 years of universityMinisters vow to end civil service 'merry go round of mediocrity' by making it easier to sack underI'm a vet and you should beware of these 4 garden plants that are harmful to dogsArgentina labor unions' 1Charlotte Hornets hire Celtics assistant coach Charles Lee to be their next head coachHow safe is AstraZeneca's Covid jab? What are the side effects? And why do victims only have a 3Ministers vow to end civil service 'merry go round of mediocrity' by making it easier to sack underPolish defense minister fends off criticism after he says he keeps an emergency backpack readyHurricanes make change in net. Go to Pytor Kochetkov for Game 3 against the RangersWhy we need more than a British Isa to move the dial on UK smaller companies
2.3295s , 6502.5703125 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Culture Connection news portal